Publications by authors named "A Elhaddad"
Article Synopsis
- B. pilosa L. is an edible herb traditionally used for healing, and a recent study conducted a detailed analysis of its extract using advanced techniques like UPLC/T-TOF-MS/MS and GC-MS.
- The study found that unsaturated fatty acids (11.38%) and sterols (39.92%) were more prevalent in the extract than saturated fatty acids (8.69%) and hydrocarbons (6.6%), with oleic and palmitic acids being the most significant.
- The extract exhibited a concentration-dependent suppression of cell proliferation in cancer cell lines and showed potential as an inhibitor for certain enzymes, although safety toxicity assessments were missing, indicating a need for further research on its therapeutic effects.
Article Synopsis
- The study investigated the expression of VEGFRs, PDGFRs, and c-Kit in pediatric patients with high-grade non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) to understand their impact on growth, invasion, and treatment outcomes.
- Out of 113 pediatric patients analyzed, about one-third showed high expression of PDGFRα, while other markers had lower expression rates; high PDGFRα and VEGFR2 were notably associated with poorer survival rates.
- The results suggest that these tyrosine kinase receptors are upregulated in NRSTS, indicating a potential for targeted therapies to improve outcomes in affected patients.
Article Synopsis
- The study aimed to evaluate the late effects and quality of life in pediatric survivors of mature B-non-Hodgkin lymphoma (NHL) after receiving treatment.
- It included 273 patients treated at Children's Cancer Hospital of Egypt, with assessments for various toxicities and quality of life conducted over at least five years.
- Results showed notable pulmonary dysfunction in 58.6% of patients, some cognitive impairments, and overall satisfactory quality of life scores, but with significant issues in the physical domain for certain groups, specifically linked to pulmonary dysfunction and older age at diagnosis.
Article Synopsis
- Autologous hematopoietic cell transplantation (AHCT) is an effective treatment for multiple myeloma, with real-world data collected from 61,725 patients revealing median overall survival of 90.2 months and median progression-free survival of 36.5 months.* -
- Cumulative relapse incidence and non-relapse mortality rates at 24 months were found to be 33% and 2.5% respectively, with better outcomes linked to factors like younger age, certain disease subtypes, and high performance status.* -
- Global variations were observed in patient outcomes based on registry data, influenced by differences in patient characteristics, use of maintenance treatments, and macroeconomic factors, highlighting the safety and effectiveness of AH
Article Synopsis
- * Both types of HCT are risky and complicated, but global collaboration among medical professionals has established it as a standard treatment for many serious blood-related illnesses, resulting in improved patient outcomes.
- * Over 1.5 million HCT procedures were performed from 1957 to 2019, and this number continues to rise globally, supported by registries and international medical societies.